Primavanserin Indications
Primavanserin is FDA-approved exclusively for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP) in adult patients. 1
FDA-Approved Indication
Primavanserin (marketed as NUPLAZID®) has a single, specific indication:
- Treatment of hallucinations and delusions associated with Parkinson's disease psychosis 1
The medication is available as:
- 34 mg capsules (standard dose)
- 10 mg tablets (for dose reduction when needed)
The recommended dose is 34 mg taken orally once daily without titration, and can be taken with or without food. 1
Critical Safety Warning
Primavanserin carries a black box warning for increased mortality in elderly patients with dementia-related psychosis. The drug is NOT approved for patients with dementia-related psychosis unless their hallucinations and delusions are specifically related to Parkinson's disease. 1
Clinical Context and Positioning
The 2019 American Geriatrics Society Beers Criteria recognizes pimavanserin (along with quetiapine and clozapine) as an exception to the general recommendation to avoid all antipsychotics in older adults with Parkinson's disease, though none of these agents is considered ideal in either efficacy or safety. 2
Primavanserin is the only FDA-approved antipsychotic specifically indicated for PDP, distinguishing it from quetiapine and clozapine which are used off-label. 3, 4, 5 This approval was based on demonstrated efficacy in treating psychotic symptoms without worsening motor function—a critical advantage since most antipsychotics directly block dopamine receptors and exacerbate parkinsonian symptoms. 6
What Primavanserin Is NOT Indicated For
Primavanserin is not approved for:
- Schizophrenia
- Dementia-related psychosis (unless specifically PD-related)
- Delirium management
- Alzheimer's disease psychosis
- Lewy body dementia psychosis (though this remains an area of clinical debate)
- General behavioral disturbances in Parkinson's disease without psychosis
The ESMO and other delirium guidelines do not include primavanserin in their pharmacological management algorithms, focusing instead on haloperidol, olanzapine, quetiapine, and other traditional agents. 7